anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A fall on stairs can be a dangerous accident. An important indicator of falling risk is the foot clearance, which is the height of the foot when ascending stairs or the distance of the foot from the step when descending. We developed an augmented reality system with a holographic lens using a visual illusion to improve the foot clearance on stairs. The system draws a vertical striped pattern on the stair riser as the participant ascends the stairs to create the illusion that the steps are higher than the actual steps, and draws a horizontal striped pattern on the stair tread as the participant descends the stairs to create the illusion of narrower stairs. We experimentally evaluated the accuracy of the system and fitted a model to determine the appropriate stripe thickness. Finally, participants ascended and descended stairs before, during, and after using the augmented reality system. The foot clearance significantly improved, not only while the participants used the system but also after they used the system compared with before.
The World Health Organization's (WHO) designation of noma as a neglected tropical disease (NTD) on 15 December 2023 marks a crucial advancement in global health efforts. This move sheds light on a condition predominantly affecting undernourished children in isolated regions of sub-Saharan Africa. Recognized as the 21st NTD, noma, or cancrum oris, is a serious condition leading to orofacial gangrene. The disease largely impacts young children and those with compromised immune systems, including individuals with human immunodeficiency virus or leukaemia. Determining the exact prevalence of noma is complex, hindered by rapid disease progression, societal stigma and a lack of reporting, especially in impoverished areas. The WHO's acknowledgment is a significant step, emphasizing the need for more in-depth research and resources to address this overlooked disease. It highlights the critical role of multifaceted prevention strategies, including economic empowerment, improved nutrition and enhanced vaccination efforts. This recognition is pivotal in guiding international health initiatives towards better outcomes for some of the most at-risk populations globally.
Facial image data of an individual is collected of the individual to provide mental state data using a first web-enabled computing device. The mental state data is analyzed to produce mental state information using a second web-enabled computing device. The mental state information is shared across a social network using a third web-enabled computing device. The mental state data is also collected from the individual through capture of sensor information. The mental state data is also collected from the individual through capture of audio data. The individual elects to share the mental state information across the social network. The mental state data may be collected over a period of time and analyzed to determine a mood of the individual. The mental state information is translated into a representative icon for sharing, which may include an emoji. An image of the individual is shared along with the mental state information.
The goal of the intervention is to help women achieve the lower bound of the GWG range recommended by the Institutes of Medicine (IOM) for a given prepregnancy BMI category (i.e., 11 lbs for obese women and 15 lbs for overweight women). The pregnancy lifestyle intervention will be delivered by trained study dieticians via individual counseling sessions: 2 in-person and 11 telephone sessions delivered on a weekly basis, followed by telephone sessions delivered every other week through the end of pregnancy.
<P>PROBLEM TO BE SOLVED: To provide use of an isolated protein complex comprising Tsg101 (tumor sensitive gene 101), and HIV (human immunodeficiency virus) GAG or GAGp6.  <P>SOLUTION: The Tsg101 interacts with the HIV GAGp6. A protein complex formed by the Tsg101 and the HIV GAG or GAGp6, as well as the Tsg101 alone, is used in screening assays for selecting compounds modulating functions and activity of the Tsg101, and a protein complex comprising the Tsg101, and the HIV GAG or GAGp6. The identified compounds are useful in inhibiting lentivirus propagation (particularly HIV propagation), and in treating HIV infection and AIDS. The protein complex can be utilized in the screening assays for selecting the compounds effective in modulating the Tsg101-HIV GAG, or GAGp6 interaction in the protein complex.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Isolated IMP-3-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce IMP-3-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors including, for example, bladder cancer, cervical cancer, cholangiocellular carcinoma, chronic myelocytic leukemia, colon cancer, rectum cancer, esophageal cancer, gastric diffuse-type cancer, non-small-cell lung cancer (NSCLC), small-cell lung cancer (SCLC), lymphoma, osteosarcoma, ovarian cancer, renal carcinoma, soft tissue tumor, testicular tumor, and HNC.
PROBLEM TO BE SOLVED: To obtain the subject composition capable of remarkably multiplying bifidus bacteria without any side reaction such as diarrhea by combining raffinose with a specific oligosaccharide in a specific ratio. SOLUTION: This bifidus bacteria multiplicaton accelerating composition comprises, as active ingredients, (A) at least one kind of oligosacchadide selected from the group consisting of lactulose, fructooligosacchdide and galactooligosaccharide and (B) raffinose in the weight ratio A/B preferably of >=1/9. For the fructooligosaccharide, e.g. 1-kestose, nystose is used, and for the gactooligosacchadide, e.g. a compound expressed by the formula Gal-(Gal)n - Glc, (Gal is a galactose residue; Glc is a glucose residue; (n) is 1 to 4) is used. For intake by human, the daily dose of this composition is preferably in the range of 0.01 to 0.5 g/kg body weight.
Pregnancy Category B

Animal reproduction studies in rats and mice revealed no evidence of fetal harm. There are, however, no adequate and well-controlled studies of tadalafil in pregnant women. Because animal reproduction studies are not always predictive of human response, tadalafil should be used during pregnancy only if clearly needed. 

Non–teratogenic effects

Animal reproduction studies showed no evidence of teratogenicity, embryotoxicity, or fetotoxicity when tadalafil was given to pregnant rats or mice at unbound tadalafil exposures up to 7 times the maximum recommended human dose (MRHD) of 40 mg/day during organogenesis. In one of two perinatal/postnatal developmental studies in rats, postnatal pup survival decreased following maternal exposure to unbound tadalafil concentrations greater than 5 times the MRHD based on AUC. Signs of maternal toxicity occurred at doses greater than 8 times the MRHD based on AUC. Surviving offspring had normal development and reproductive performance [see Nonclinical Toxicology (13.3)].
Postoperative adjuvant therapy for biliary system tumors has long lacked a universally recognized standard regimen. The BILCAP trial results showed a survival benefit with adjuvant therapy. The BILCAP study filled the gap in the field of postoperative adjuvant therapy for biliary system tumors. In the study, the median overall survival (OS) in the capecitabine group was 51.1 months, compared to 36.4 months in the observation group. The median recurrence-free survival (RFS) in the capecitabine group was 24.4 months, compared to 17.5 months in the observation group. Compared to the observation group, adjuvant therapy with capecitabine significantly prolonged both OS and RFS, and the capecitabine group had good tolerability with no chemotherapy-related deaths. In addition, the ASCOT study reported that adjuvant therapy with tegafur after surgery could prolong the RFS rate in patients. Therefore, in the NCCN and CSCO guidelines, capecitabine is listed as a category I recommendation for adjuvant therapy of biliary tract malignancies (BTC). However, it is regrettable that the latest reports show that in the intention-to-treat (ITT) population, the BILCAP trial failed to reach its primary endpoint of OS, with the median OS in the study group and the control group being 51.1 months and 36.4 months, respectively \[HR=0.81, 95% CI(0.63,1.04), P=0.097\]. Furthermore, in clinical practice, the use of capecitabine or tegafur after surgery in patients with cholangiocarcinoma at high risk of recurrence still has a high recurrence rate. Therefore, there is still a significant unmet need in the clinical postoperative adjuvant therapy for biliary tract malignancies.Based on the above background, we plan to carry out a randomized, open, and comparative study to observe the efficacy and safety of Adebrelimab combined with capecitabine for adjuvant treatment in patients with biliary tract malignancies after surgery, and to explore treatment methods to improve the efficacy of postoperative adjuvant treatment for cholangiocarcinoma.
The control group will receive 30ml of 5% glucose. Both provider and patient will be double-blinded until the conclusion of the study.
BACKGROUND: Globally, sepsis has been identified as one of the leading causes of preventable childhood mortality and morbidity. Previous studies on intensive care patients estimated that approximately 30% of children with sepsis experience some form of disability at discharge. Development of care has seen growing numbers of children treated for sepsis not requiring a PICU admission; however, outcomes in this population are yet to be understood. Further focus is required to understand sepsis survivorship across the wider population to address knowledge gaps and morbidity burden in the broader surviving population.
AIMS: To assess the cognitive, physical, emotional and social health of children surviving sepsis 2 years after hospital discharge.
STUDY DESIGN: A prospective, observational cohort study.
RESULTS: Two hundred and thirty-two children will be screened, 2 years after their hospital admission, and approached for participation in this study. Children who are <18 years of age at follow-up, treated for sepsis-related organ dysfunction or septic shock in Queensland between October 2018 and December 2019, will be included. Children who are deceased at follow-up, under care of the state, or require English interpreters will be excluded from participation. Data will be collected through an online follow-up survey comprising validated caregiver-reported questionnaires covering the four Post Intensive Care Syndrome-paediatrics (PICS-p) domains (cognitive, physical, emotional and social health; Manning et al. Pediatr Crit Care Med, 2018, 19, 298-300). The primary outcome is an adaptive behaviour of the participants assessed using the Vinelands-3 tool. Secondary outcomes will include neurodevelopment, quality of life, child distress, overall function, executive function, caregiver's distress and caregiver's stress. Analysis of variance (ANOVA), Kruskal-Wallis and Fisher's exact test/chi-squared tests will be used for statistical analyses. No adjustments will be made for multiple comparisons but it is acknowledged that comparisons made in this study are exploratory.
RELEVANCE TO CLINICAL PRACTICE: With more children surviving sepsis, there is a need for a more comprehensive assessment of patient and family outcomes to allow support structures for families leaving the hospital after sepsis. This study is expected to inform clinicians and stakeholders of patient and family well-being after sepsis survivorship.
Participants will attend two laboratory sessions. At the first session, participants will complete a socio-evaluative speech task, which is a widely used, highly effective way to investigate stress responses in a laboratory setting. Participants will prepare and deliver a brief, 3-minute speech defending themselves against an alleged transgression (e.g., running a stop sign). The speech will be delivered in front of a video camera, a mirror and an audience (the interviewer and another staff member). Participants will be told that their non-verbal behaviors are being evaluated. At the second session, participants will rest quietly for the same period as the speech task, in the absence of the stressor.
PURPOSE:To obtain an injection formulation of <11>C labeled methyl compound steadily and continuously through fully automated remote operation. CONSTITUTION:<11>C methyl iodide is produced in a first reaction flask F1 from <11>C carbon dioxide produced in a <11>C nuclide material production unit. It is passed through an acid capturing tube 11 and a dryer tube 12 to produce an anhydrous <11>C methyl iodide which is then caused to reaction a compound to be labeled in a second reaction flask F2 thus producing a <11>C labeled methyl compound. It is then fed through a chromatography unit 13 into a third reaction flask F3 where an isotonic physiological saline solution is produced. Subsequently, it is introduced to a pH conditioning flask F4 in order to condition pH and the volume of solutmon. Finally, it is passed through a pyrogen aclsorber 23 and a sterilization filter 24 and filled in an ingectnon container 25, e.g. a vial.
The present invention provides a novel process for producing a calcium phosphate cement or filler which hardens in a temperature dependent fashion in association with an endothermic reaction.    In the reaction a limited amount of water is mixed with dry calcium phosphate precursors to produce a hydrated precursor paste. Hardening of the paste occurs rapidly at body temperature and is accompanied by the conversion of one or more of the reactants to poorly crystalline apatitic calcium phosphate. The hardened cements, fillers, growth matrices, orthopedic and delivery devices of the invention are rapidly resorbable and stimulate hard tissue growth and healing. A composite material is provided including a strongly bioresorbable, poorly crystalline apatitic calcium phosphate composite and a supplementary material.  The supplementary material is in intimate contact with the hydroxyapatite material in an amount effective to impart a selected characteristic to the composite. The supplemental material may be biocompatible, bioresorbable or non-resorbable. A method for treating a bone defect also is provided by identifying a bone site suitable for receiving an implant, and introducing a strongly resorbable, poorly crystalline apatitic calcium phosphate at the implant site, whereby bone is formed at the implant site. The implant site may be a variety of sites, such as a tooth socket, non-union bone, bone prosthesis, an osteoporotic bone, an intervertebral space, an alveolar ridge or a bone fracture.
Aliskiren tablets are contraindicated in patients less than 2 years of age [see Contraindications (4)].

Aliskiren tablets are indicated for treatment of hypertension in pediatric patients 6 years of age and older weighing 50 kg or more.The safety and effectiveness of aliskiren have been established in pediatric patients 6 years of age and older weighing 20 kg or more, but aliskiren tablets are not approved in patients 6 years of age and older weighing 20 kg to less than 50 kg because of the lack of an appropriate dosage form. Use of aliskiren tablets in pediatric patients 6 years and older is supported by evidence from a pharmacokinetic trial and two randomized, double-blind clinical trials in pediatric patients with hypertension 6 years to 17 years of age weighing 20 kg or more [see Clinical Pharmacology (12.3), Clinical Studies (14.4)]. The safety and effectiveness of aliskiren tablets have not been established in pediatric patients younger than 6 years of age and patients less than 20 kg. Avoid use in patients 2 years to less than 6 years and patients weighing less than 20 kg due to the limited information about aliskiren metabolism and exposures in this age group. No data are available in pediatric patients weighing less than 20 kg or in pediatric patients with a glomerular filtration rate <30 mL/min/1.73 m2.

Juvenile Animal Toxicity Data   


Toxicology studies in juvenile animals the approximate human age equivalent of children less than 2 years of age identified 85-to 385-fold increased systemic exposure to aliskiren compared to adult rats. The increased aliskiren exposure in juvenile rats was attributed to immaturity in aliskiren drug transporters and metabolizing enzymes. Increased aliskiren exposures were associated with premature deaths. Although a definitive pathology-based cause of death could not be ascertained, the premature deaths were attributed to the immaturity in aliskiren metabolism. The nonclinical findings suggest a distinct age-dependent relationship between dose and exposure.

Neonates with a history of in utero exposure to aliskiren tablets

If oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function.
Low levels of physical activity in childhood are related to obesity and risk for diabetes and cardiovascular disease. This translational study is an attempt to take interventions that have been shown to be effective in highly controlled setting and implement them in the community. We will utilize a form of a single case design (i.e., stepped-wedge or multiple-baseline design), which is an underused, though promising, alternative to the traditional, parallel-group randomized trial in which each study participant acts as his/her own control. Participants will be randomized to baseline periods of varying length such that the change in the study outcome can be causally attributed to introduction of the intervention. In accordance, families will be randomized to a 2, 4, or 6-week baseline period before being administered the P-Mobile app based intervention. All families will receive the same P-Mobile intervention following the baseline period. The P-Mobile intervention will be delivered to parents via the P-Mobile smartphone app; it consists of 10 lessons designed to increase physical activity in children. The parents will also receive notifications designed to prompt physical activity, motivate, and remind parents of lesson content. The intervention will also utilize an adaptive step goal approach, in which the step goal is modified based on each participant's individual performance. The primary aims of the study are: (1) To estimate several parameters, which will allow us to redesign our study as a single case design (and to conduct simulation-based power calculations): (a) average day-to-day variability in daily steps during the baseline period, (b) average autocorrelation in the daily step data, and (c) average effect size at 2 weeks, 4 weeks, and 6 weeks after introduction of the intervention. (2) To test the feasibility of the P-Mobile app (3) To demonstrate our ability to recruit participants from targeted neighborhoods.
Total daily Busilvex dose (3.2 to 4.8 mg/kg/day, based on body weight) according to authorised dosage for children and adolescents administered i.v. as part of the background conditioning regimen on four consecutive days (days -7, -6, -5 and -4); given in 1, 2, or 4 portions per day according to the respective hospital's standard.
Risk Summary

Based on its mechanism of action [see Clinical Pharmacology (12.1)], CYRAMZA can cause fetal harm when administered to a pregnant woman. There are no available data on CYRAMZA use in pregnant women. Animal models link angiogenesis, VEGF and VEGFR2 to critical aspects of female reproduction, embryo-fetal development, and postnatal development. No animal studies have been conducted to evaluate the effect of ramucirumab on reproduction and fetal development. Advise a pregnant woman of the potential risk to a fetus. 

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. 

Data

Animal Data

No animal studies have been specifically conducted to evaluate the effect of ramucirumab on reproduction and fetal development. In mice, loss of the VEGFR2 gene resulted in embryo-fetal death and these fetuses lacked organized blood vessels and blood islands in the yolk sac. In other models, VEGFR2 signaling was associated with development and maintenance of endometrial and placental vascular function, successful blastocyst implantation, maternal and feto-placental vascular differentiation, and development during early pregnancy in rodents and non-human primates. Disruption of VEGF signaling has also been associated with developmental anomalies including poor development of the cranial region, forelimbs, forebrain, heart, and blood vessels.
The invention discloses a method to separate and purify cefminox sodium. Solvent is prepared from trichloromethane, ethyl acetate, carbinol and water, with the upper phase being stationary and the lower phase being mobile. The whole column of a high-speed countercurrent chromatograph is filled with stationary phase solvent and then the mobile phase solvent is pumped into the column; the raw material of cefminox sodium is dissolved in the solvent at the lower phase and the material is fed by an injection valve; above 98% of the product is collected according to the map of the detector and then the solvent is removed to obtain refined cefminox sodium. The method is good in effect and the product is of high purity. The cefminox sodium can be further froze and dried to prepare freeze-dried powder injection. The method is good in separation effect and the product is of high purity.
The invention relates to the field of blood purification, particularly relates to a dual-chamber bag amino acid peritoneal dialysis solution and a preparation method thereof. The dual-chamber bag amino acid peritoneal dialysis solution comprises a first chamber bag and a second chamber bag, wherein the volume ratio of the first chamber to the second chamber is 2.5:7.5 to 4.5:5.5. The first chamber contains amino acid and electrolyte, the total amount of the amino acid is 7.8-14.2 g/L, and the pH is 4.0-7.0. The second chamber contains a buffer solution containing acids such as organic acids, inorganic acids, analogues and their combinations and with the pH of 8.0-9.0. The liquid in the first chamber and the liquid in the second liquid can be mixed into a solution with the pH of 6.5 to 7.5 before the liquid is injected into a patient. The dialysis solution conforms to the physiology of a human body, and abdominal pain caused by slightly lower or higher pH in the peritoneal dialysis process is relieved. In addition, by introducing bicarbonate, the lactate content in a formula is reduced, and accordingly the risk of acidosis exacerbation of the patient is reduced.